Not affected by mutant strains!

From inactivated vaccines to recombinant protein vaccines to mRNA vaccines.

Today, a paper in "Nature" magazine gives us the hope of remedying the loopholes

Whether it is congenital immunodeficiency or secondary immunodeficiency caused by cancer, infection, etc.

To provide effective and long-lasting protection for such people, one strategy is to induce specific T cell immunity against the new coronavirus

Compared with other types of vaccines that have already come out, the development of peptide vaccines does not seem to be so smooth

The main active ingredient of this vaccine is specific T cell epitopes from a variety of new coronavirus proteins (including the familiar spike protein, nucleoprotein shell, membrane glycoprotein, envelope glycoprotein, etc.

In the first clinical evaluation of CoVac-1, the research team recruited 36 volunteers between the ages of 18 and 80, and they received a single dose of the peptide vaccine

▲T cell responses of volunteers of different ages after vaccination (picture source: reference [1])

The results showed that none of the volunteers had serious adverse reactions

Another important conclusion is that compared with the reduced protection efficiency of many existing vaccines in the face of mutants, the T cell response induced by this peptide vaccine is not affected by any known new coronavirus mutants (including α, β, γ).

▲The effect of the new crown mutant strain on vaccine peptides (picture source: reference [1])

Therefore, this test showed good safety and induced a T cell immune response

Currently, Phase 2 clinical trials for CoVac-1 are underway, and whether this vaccine can finally enter the market remains to be tested

Note: The original text has been deleted

Reference materials:

[1] Heitmann, JS et al.